Jeil Pharmaceutical "Onconic Therapeutics Reveals Clinical Results of New GERD Drug at US ASCPT"

[Asia Economy Reporter Hyunseok Yoo] Jeil Pharmaceutical announced on the 17th that the results of the Phase 1 clinical trial (MAD, multiple ascending dose) of ’JP-1366’, a new drug for gastroesophageal reflux disease developed by its subsidiary Onconic Therapeutics (hereinafter Onconic), were presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT).

Founded in 1990, ASCPT is a society established to advance patient-centered therapeutic benefits and the practice of clinical pharmacology and translational medicine. It currently consists of over 2,300 experts and is a leading global organization in the field.

Professor Seunghwan Lee of Seoul National University, who conducted the clinical trial, explained, "JP-1366 showed excellent tolerability in healthy adults, with overall responses similar to the comparator drug. In particular, its acid suppression effect was outstanding, showing potential as a new alternative treatment to PPIs, which are gastric function protective inhibitors."

Onconic’s gastroesophageal reflux disease treatment (JP-1366) is a promising new drug candidate classified as a P-CAB (potassium-competitive acid blocker), overcoming the limitations of existing PPI (proton pump inhibitor) treatments. It was selected in 2017 as a new drug development support project under the Ministry of Health and Welfare’s advanced medical technology development program. Currently, Phase 2 clinical trials targeting patients with gastroesophageal reflux disease have been completed, and preparations are underway to enter Phase 3 trials.

Kim Jeonghoon, CEO of Onconic, stated, “Through this poster presentation, we were able to confirm global market interest in the development of next-generation anti-ulcer drugs, and we will accelerate research and development to become the top new drug in the P-CAB category.”

Currently, PPIs are the most widely used drugs for treating reflux esophagitis by suppressing gastric acid secretion, but due to various drawbacks and controversies over side effects, the pharmaceutical industry continues to strive to find alternative treatments to PPIs.